Company Overview - Nilfisk Holding A/S is a leading global provider of professional cleaning equipment and services, founded in 1906 by Danish engineer P.A. Fisker [4] - The company generates over 90% of its sales from professional markets, with the remainder from consumer products such as floorcare equipment and vacuum cleaners [4] - Nilfisk operates in more than 100 countries and has six manufacturing sites located in the US, Mexico, Hungary, Italy, and China, employing approximately 4,500 people [5] Financial Performance - In 2024, Nilfisk reported revenue of €1,027.9 million, with the largest market being the US, accounting for 28% of total revenue, followed by Germany (14%), France (10%), Denmark (7%), and the UK (4%) [5] Takeover Offer - On December 11, 2025, Nilfisk announced an agreement with Freudenberg Home and Cleaning Solutions GmbH to make an all-cash voluntary recommended public takeover offer at a price of DKK 140 per share [1] - The offer document, including an acceptance form, has been approved by the Danish Financial Supervisory Authority [1][2] - The Board of Directors of Nilfisk will issue a statement regarding the offer, advising shareholders to read both the offer document and the board statement before making a decision [2]

Core Viewpoint - The announcement details a change in the shareholding of Jyske Bank A/S, indicating that the bank holds 3,092,063 shares, which represents 5.03% of its share capital as of January 6, 2026 [1]. Group 1 - Jyske Bank A/S, with business registration number (CVR) 17616617, is located at Vestergade 8-16, 8600 Silkeborg [1]. - The shareholding consists of both direct and indirect holdings [1]. - The announcement is made in accordance with S.31 of the Danish Capital Market Act [1].

Core Viewpoint - Bavarian Nordic A/S has initiated a share buy-back program with a total budget of DKK 500 million for 2026, starting with a first tranche of DKK 150 million aimed at adjusting the capital structure [1][2]. Group 1: Share Buy-Back Program Details - The share buy-back program is authorized by the annual general meeting held on April 9, 2025, and complies with EU regulations on market abuse [2]. - The program will be managed by Nordea, which has been appointed as the lead manager to execute the buy-back independently [3]. - The buy-back will commence on January 7, 2026, and is expected to be completed by February 13, 2026, with a maximum of 1,500,000 shares to be repurchased [7]. Group 2: Transaction Terms - The maximum aggregate purchase price for the first tranche is DKK 150 million, and the maximum number of shares that can be purchased on any single trading day is limited to 25% of the average daily trading volume over the preceding 20 trading days [7]. - Prior to the program, Bavarian Nordic held 966,845 treasury shares, which is 1.22% of the company's share capital [5].

Core Insights - Orrön Energy AB has made significant progress in its greenfield platform, enhancing the value and maturity of its project portfolio, particularly in the UK and Germany [1][3] UK Developments - The company has secured grid connections for six large-scale projects in the UK, with a total estimated capacity of 2.9 GW, including three solar energy projects (1.8 GW) and three data center projects (1.1 GW) [1] - Binding grid offers and additional details regarding grid connection dates are expected in the third quarter of 2026, with projects ready to permit once final agreements are issued [1] German Developments - In Germany, three solar energy projects with a combined capacity of approximately 250 MW have received municipal approvals, contributing to the company's growing project pipeline [2] - The company has advanced a significant pipeline of large-scale battery projects and expects to receive grid confirmation early this year [2] - Recent sales processes have resulted in the sale of 310 MW of projects for a total consideration of €18 million, contingent on reaching key development milestones [2] Financial Outlook - The CEO of Orrön Energy expressed confidence in the company's progress, noting an average sales price of around €55,000 per MW expected in 2025, which is anticipated to deliver significant value moving forward [3]

Core Insights - Basilea Pharmaceutica Ltd has entered into a collaboration with Prokaryotics Inc. to develop a first-in-class broad-spectrum antifungal targeting severe invasive infections [1][2] - The partnership aims to address the unmet medical needs for antifungal treatments against pathogens like Candida and Aspergillus, which are critical for immunocompromised patients [2][4][5] - Basilea will handle clinical development and commercialization, while Prokaryotics will receive milestone payments and royalties based on sales [3] Company Overview - Basilea is a commercial-stage biopharmaceutical company focused on developing innovative drugs for severe bacterial and fungal infections, with existing products like Cresemba and Zevtera [8] - The company has a robust anti-infective R&D pipeline, indicating a strong commitment to addressing medical needs in this area [3][8] - Prokaryotics specializes in discovering novel anti-infective drugs, particularly targeting multidrug-resistant infections, and emphasizes the need for new antifungal agents with unique mechanisms of action [6]

Group 1 - Vivoryon Therapeutics N.V. is a clinical stage biotechnology company focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases [2] - The company's lead program, varoglutamstat, is a first-in-class orally available QPCT/L inhibitor being evaluated for the treatment of diabetic kidney disease [2] - Vivoryon will participate in several upcoming medical and investor conferences, including the J.P. Morgan Healthcare Conference, UBS European Healthcare Conference, and World Congress of Nephrology [1] Group 2 - The J.P. Morgan Healthcare Conference will take place in San Francisco, USA from January 12-14, 2026 [1] - The UBS European Healthcare Conference is scheduled for March 3-4, 2026 in London, UK [1] - The World Congress of Nephrology will be held in Yokohama, Japan from March 28-31, 2026 [1]

Core Viewpoint - Addex Therapeutics announced that its spin-out company, Neurosterix, has initiated a Phase 1 clinical study of NTX-253, a positive allosteric modulator for the treatment of schizophrenia, marking a significant milestone for both companies [1][2] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4] - The company retains a 20% equity interest in Neurosterix, which was spun out in April 2024 and raised $65 million in Series A financing [2][4] Product Development - NTX-253 is a selective, orally available positive allosteric modulator of the muscarinic M4 receptor, designed to treat schizophrenia by potentially reducing psychosis symptoms without the side effects associated with traditional dopamine antagonists [1][3] - Preclinical studies have shown that NTX-253 has robust antipsychotic-like activity and a favorable safety profile, supporting its advancement into first-in-human clinical studies [3] Market Position - The M4 muscarinic receptor is a validated target for treating schizophrenia, offering a novel therapeutic approach compared to traditional antipsychotics that primarily target dopamine receptors [3] - Current antipsychotics can induce metabolic, cognitive, and motor side effects, which M4 PAMs aim to avoid while still providing therapeutic benefits [3]

Core Insights - The company reported a robust start to Q1 Fiscal 2026, confirming all financial objectives for the year [1][3][20] Financial Performance - Total Revenues reached €308 million in Q1 Fiscal 2026, reflecting a 9.0% organic growth and a 6.6% reported growth compared to Q1 Fiscal 2025 [2][10][26] - Operating revenue was €268 million, up 9.1% organically and 7.5% reported, driven primarily by Employee Benefits [2][12][29] - Float revenue stood at €40 million, showing an 8.5% organic growth and a 0.8% reported growth [2][13][26] Regional Performance - Continental Europe generated €121 million in revenues, with a slight organic decline of 0.4% but a reported growth of 1.4% [2][28] - Latin America saw revenues of €131 million, achieving a significant organic growth of 17.2% and a reported growth of 16.7% [2][28] - The Rest of the World contributed €56 million, with an organic growth of 12.9% but a reported decline of 2.4% [2][28] Business Segments - Employee Benefits revenue reached €271 million, reflecting an 11.2% organic growth and an 8.8% reported growth [2][27] - Other Products & Services generated €37 million, down 4.6% organically and 7.1% reported [2][27] Strategic Initiatives - The company successfully completed acquisitions of Skipr and ProEves, enhancing its multi-benefit offerings in Belgium, France, and India [4][20][19] - A solid M&A pipeline is expected to support long-term growth ambitions [4][19] Market Conditions - The company is navigating a challenging regulatory environment in Brazil but remains confident in its operational and financial performance [5][6] - Employee Benefits business performance was bolstered by strong new client acquisition and a net retention rate of 100% [6][8]

Core Insights - Technip Energies has been awarded two significant contracts by Bharat Petroleum Corporation Limited (BPCL) for projects at the Bina and Mumbai refineries in India, reinforcing a long-standing collaboration between the two companies [1][4]. Contract Details - The first contract involves Engineering, Procurement, Construction and Commissioning (EPCC) for new polypropylene and Butene-1 units at the Bina refinery, with a production capacity of 550 KTPA of polypropylene and 50 KTPA of Butene-1, which are essential for various products [2]. - The second contract includes Engineering, Procurement and Construction management (EPsCm) services for a 3 MMTPA Petro Resid Fluidized Catalytic Cracker Unit (PRFCC) at the Mumbai refinery, marking it as India's first PRFCC unit [3]. Financial Impact - The total value of the two contracts is estimated to be between €250 million and €500 million, contributing to Technip Energies' revenue and recorded in Q4 2025 [5]. Company Background - Technip Energies is a global technology and engineering firm with over 50 years of operational experience in India, focusing on advancing the country's energy infrastructure through large-scale projects [4][7]. - The company generated revenues of €6.9 billion in 2024 and is listed on Euronext Paris, with a workforce of over 17,000 employees across 34 countries [8].

Group 1 - TextMagic AS has appointed Getter Grünmann as an additional member of the Management Board, effective January 7, 2026, for a term of three years [1] - The Management Board of TextMagic AS will continue to operate with two members [1] - Getter Grünmann, currently the Chief Financial Officer, will oversee the financial management of TextMagic AS as a member of the Management Board [2]